#1 AACR 第3天(April 7th)的主要看点 - San Diego, April 7th
发表于 : 2024年 4月 6日 15:32
Session Title: PO.ET06.01 - Identification of Molecular Targets
Session Type: Poster Session
Track(s): Experimental and Molecular Therapeutics, Molecular/Cellular Biology and Genetics
Session Time: April 7, 2024, 1:30 PM - 5:00 PM
The session includes 30 poster presentations on topics related to the identification of molecular targets for cancer therapy, across a range of cancer types. Some key highlights include:
- Exploiting therapeutic bottlenecks to identify new immunotherapy targets
- Targeting PDZK1 and EGFR degradation in triple-negative breast cancer
- Identifying isoform switching events linked to prognosis in esophageal adenocarcinoma
- Investigating the antiproliferative effects of natural compounds in cancer cells
- Targeting non-canonical disulfide isomerases and PROX1 in cancer
- Using AI-powered analysis of CNTN4 and PD-L1 expression across cancers
- Determining the role of TRIM31 in esophageal adenocarcinoma
- Evaluating the Idylla IDH1-2 mutation assay for glioma
- Targeting CYR61, YBX1, MCL1, PDE4D, JAK/STAT, and PDE7 in various cancer types
- Sensitizing triple-negative breast cancer to radiation using fisetin
- Modulating HER4 isoforms in estrogen-stimulated breast cancer models
- Targeting UHRF1 degradation in small cell lung cancer
- Identifying PSMC6 as essential for cisplatin-resistant ovarian cancer
- Potential therapeutic targets in gastric cancer with peritoneal dissemination
- Targeting SLC22A17 and FABP4 in triple-negative breast cancer and liver cancer
- Identifying SORL1 as a regulator of chemoresistance in ovarian cancer
- Evaluating the pan-quadruplex drug QN-302 in pancreatic cancer
- Deciphering the menin-MLL complex dependency in hepatocellular carcinoma
Session Type: Poster Session
Track(s): Experimental and Molecular Therapeutics, Molecular/Cellular Biology and Genetics
Session Time: April 7, 2024, 1:30 PM - 5:00 PM
The session includes 30 poster presentations on topics related to the identification of molecular targets for cancer therapy, across a range of cancer types. Some key highlights include:
- Exploiting therapeutic bottlenecks to identify new immunotherapy targets
- Targeting PDZK1 and EGFR degradation in triple-negative breast cancer
- Identifying isoform switching events linked to prognosis in esophageal adenocarcinoma
- Investigating the antiproliferative effects of natural compounds in cancer cells
- Targeting non-canonical disulfide isomerases and PROX1 in cancer
- Using AI-powered analysis of CNTN4 and PD-L1 expression across cancers
- Determining the role of TRIM31 in esophageal adenocarcinoma
- Evaluating the Idylla IDH1-2 mutation assay for glioma
- Targeting CYR61, YBX1, MCL1, PDE4D, JAK/STAT, and PDE7 in various cancer types
- Sensitizing triple-negative breast cancer to radiation using fisetin
- Modulating HER4 isoforms in estrogen-stimulated breast cancer models
- Targeting UHRF1 degradation in small cell lung cancer
- Identifying PSMC6 as essential for cisplatin-resistant ovarian cancer
- Potential therapeutic targets in gastric cancer with peritoneal dissemination
- Targeting SLC22A17 and FABP4 in triple-negative breast cancer and liver cancer
- Identifying SORL1 as a regulator of chemoresistance in ovarian cancer
- Evaluating the pan-quadruplex drug QN-302 in pancreatic cancer
- Deciphering the menin-MLL complex dependency in hepatocellular carcinoma